American Society of Addiction Medicine
American Society of Addiction Medicine
Lead: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Lead: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Lead: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population
Tuesday 11th June 2024
Explore how semaglutide might reduce alcohol use disorder, alongside other key studies on addiction medicine. Stay informed with this insightful episode.
6 minutes
Informative
Educational
Hopeful
Supportive
Eye-opening
About this podcast
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Episodes:
140 (View all)
Do you want to link to this podcast?
Get the buttons here!Semaglutide's Role in Reducing Alcohol Use Disorder: New Insights
Episode Overview
- Semaglutide shows promise in reducing alcohol use disorder.
- Ketamine abuse leads to significant reductions in cortical thickness.
- Telemedicine is crucial for women with opioid use disorder.
- Smoking-related healthcare costs are extremely high.
- Personal loss due to drug overdose affects millions.
"Patients who received semaglutide had much lower rates of incident AUD compared to those receiving non-GLP1RA medications"
In this episode of 'This Week in Addiction Medicine from ASAM', the spotlight is on a fascinating study published in Nature Communications. The research explores the potential benefits of semaglutide, a medication primarily used for treating obesity, in reducing the incidence and recurrence of alcohol use disorder (AUD). Patients treated with semaglutide showed significantly lower rates of AUD compared to those on other medications like naltrexone and topiramate.
This finding hints at semaglutide's promise in the real-world population and underscores the need for further clinical trials to confirm these results. The episode also covers a range of other compelling studies. One highlights the adverse effects of ketamine abuse, revealing widespread reductions in cortical thickness among users. Another study reviews digital health interventions for women with opioid use disorder, emphasising the importance of telemedicine and other tech-based solutions.
There's also a deep dive into the financial burden of smoking-related healthcare costs, showing a staggering $13.6 billion in annual expenditures for current smokers with chronic lower respiratory disease. Additionally, the episode touches on the personal impact of drug overdose, noting that 82 million U.S. adults have experienced loss due to overdose, with significant implications for addiction policy.
The episode rounds off with a discussion on the age-dependent risks of cannabis use, particularly its association with psychotic disorders in younger individuals. For anyone interested in the latest findings and trends in addiction medicine, this episode offers a treasure trove of information. It provides a comprehensive look at how various substances and treatments impact both individual health and broader public health concerns. Tune in to stay informed and gain new perspectives on addiction medicine.